GT Biopharma (GTBP) Earnings Analysis

GT Biopharma (GTBP) next reports earnings on 2026-08-13, consensus EPS -0.08 USD. Last quarter (2026-05-15) it missed with EPS -0.11 USD vs -0.08 USD est (-37.5%). It has beaten estimates in 3/8 recent quarters (38%). Trailing P/E -0.05.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GTBP next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.08 USD
Revenue estimaten/a

GTBP earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.11 USD-0.08 USD-37.5%Miss
2026-03-02-2.22 USD-0.22 USD-909.1%Miss
2025-11-14-0.83 USD-0.38 USD-118.4%Miss
2025-08-14-0.55 USD-0.68 USD+19.1%Beat
2025-05-15-0.76 USD-0.64 USD-18.8%Miss
2025-02-21-1.66 USD-1.55 USD-7.1%Miss
2024-11-14-1.53 USD-2.7 USD+43.3%Beat
2024-08-14-2.24 USD-2.7 USD+17%Beat

Beat rate: 3/8 (38%) over reported quarters with consensus data.

GTBP valuation and analyst view

Trailing P/E-0.05
Trailing EPS-1.57626 USD
Price / book1.38
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (4 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is GT Biopharma (GTBP)'s next earnings date?

GT Biopharma is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.08 USD.

Did GTBP beat earnings last quarter?

In its 2026-05-15 report, GTBP posted EPS of -0.11 USD versus a -0.08 USD estimate — a miss of 37.5%.

What is GTBP's earnings track record?

Over the last 8 reported quarters with consensus data, GTBP beat estimates 3 times (38%).

What is GTBP's current P/E ratio and EPS?

GTBP trades at a trailing P/E of -0.05 on trailing EPS of -1.576262296861896 USD.

What do analysts rate GTBP?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell).